Disclaimer. This site reads publicly available research papers and corporate filings and explains what they say. It is not investment advice and does not recommend buying or selling any security. Historical cases shown here are computed from public data; the sample sizes are small and are not a basis for prediction. We do not answer questions about individual stocks.
Readouts · Company page
Chugai Pharmaceutical (中外製薬 · Chugai)
Company facts
- Status
- TSE 4519
- Links
- Filings · EDINET · Quote · Yahoo!ファイナンス
- Source
- EDINET
Financial summary (from filings)
| 2023 | 2024 | 2025 | |
|---|---|---|---|
| Revenue | 1,111,367 | 1,170,611 | 1,257,941 |
| Operating income | 439,174 | 542,002 | 598,833 |
| Net income | 325,472 | 387,317 | 434,012 |
| Total assets | 1,932,547 | 2,208,373 | 2,468,595 |
| Total liabilities | 306,967 | 306,873 | 442,862 |
| Total equity | 1,625,580 | 1,901,499 | 2,025,732 |
Unit: JPY million · Consolidated statements · Source EDINET 有価証券報告書
Figures are copied from the filing with only the unit changed. No growth rates or assessments are shown.
Readouts that mention this company
National R&D projects (NTIS)
16
item
4,297,000,000
Cumulative government R&D funding (KRW)
Largest projects
- 골 형성을 촉진하는 신규기전의 골다공증 치료제 신약후보물질 개발 2008 · 지식경제부
- 골 형성을 촉진하는 신규기전의 골다공증 치료제 신약후보물질 개발 2009 · 지식경제부
- Wnt 신호전달 억제를 통한 혁신 항암제의 개발 2007 · 산업자원부
Korean patent filings (KIPRIS)
국내 출원인 표기 없음
Papers with affiliated authors (OpenAlex)
No records
Companies in the same readouts
- Dong-A ST
- Eli Lilly
- Hangzhou Zhongmei Huadong
- Jiangsu Hengrui
- Eccogene
- Novo Nordisk
- Hanmi Pharmaceutical
- LG H&H
Last updated 2026-09-21